Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hemispherx Completes Upgraded Alferon Facility | Contract Pharma
Breaking News

Hemispherx Completes Upgraded Alferon Facility

Integrates continuous flow manufacturing technology

Hemispherx Biopharma, Inc. has completed its new manufacturing site in New Brunswick, NJ, which now encompasses more than 43,000 sq.-ft. The $8 million in upgrades provides higher capacity and a more cost effective manufacturing process for Alferon N Injection, which is the only FDA-approved natural alpha interferon.
 
The company was able to increase efficiency by integrating continuous flow manufacturing technology throughout the process, improving costs, enhancing yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety.
 
A 600-liter bioreactor was installed instead of a labor-intensive method using 100 x 6 liter flasks for the same size batch, which has eliminated ~ 80% of the manpower previously needed for this part of the process.
 
In March 2008, the company had stopped manufacturing and marketing Alferon N Injection due to high labor costs and low capacity, which limited commercialization potential.
 
The FDA will need to re-affirm the amended Biological License Application (BLA) for the facility, but the company is anticipating having commercial product available for distribution by Armada Healthcare by late 2015.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters